CN107998396A - A kind of target spot of oncotherapy and its application - Google Patents
A kind of target spot of oncotherapy and its application Download PDFInfo
- Publication number
- CN107998396A CN107998396A CN201610952945.2A CN201610952945A CN107998396A CN 107998396 A CN107998396 A CN 107998396A CN 201610952945 A CN201610952945 A CN 201610952945A CN 107998396 A CN107998396 A CN 107998396A
- Authority
- CN
- China
- Prior art keywords
- btn3a3
- expression
- btn3a2
- tumour
- lsectin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Target spot and its application the invention discloses a kind of oncotherapy.The present invention is experimentally confirmed:LSECtin, BTN3A2 and BNT3A3 are embodied in the promotion promoted in the formation of tumour cell ball, the expression of dryness transcription factor and mouse tumor model to tumor progression by promoting the maintenance of tumour cell dryness to promote tumor progression;Tumor progression can effectively be slowed down by suppressing LSECtin and BTN3A2 and BTN3A3 interactions, and being embodied in reduces Tumor incidence and slow down gross tumor volume growth.
Description
Technical field
The invention belongs to biological technical field, and in particular to a kind of target spot of oncotherapy and its application.
Background technology
Global tumor incidence is in rising trend always since the late 1970s.At present for the treatment of breast cancer
Means mainly include operation, radiotherapy, chemotherapy, endocrine therapy, Biological target therapy and traditional Chinese medicine auxiliary treatment etc., perplex tumour
The root problem for the treatment of is the recurrence after resistance and healing to medicine.Research shows, the basic original of the resistance to the action of a drug and recurrence
Because being the lifting of tumour cell dryness.For example, with estrogen receptor (ER), progesterone receptor (PR), epidermal growth factor receptor
The triple negative breast cancer that body 2 (HER2) feminine gender is characterized often is considered the tumour dryness for possessing higher.Also research knot
Fruit shows that most of non-three negative breast cancer patients, are often recurred in the form of triple negative breast cancer, this is to cause recurrence breast
Adenocarcinoma tumor has the reason for more high drug-resistance, stronger transfer ability.However, since triple negative breast cancer suffers for want of medical supplies target spot,
There is presently no the therapeutic scheme for curing triple negative breast cancer.
The dryness of tumour is by three diversity of gene, epigenetic and tumor microenvironment factor regulation and control.Due to tumour
Cell is there are height heterogeneity, therefore, from gene diversity and epigenetic angle, it is difficult to propose effective treatment side
Case.In contrast, the immunocyte of tumor microenvironment infiltration is made by maintenance of the reciprocation to tumour cell dryness with promoting
With because it has become with stronger application prospect the hot spot of research.Basic principle based on immunotherapy of tumors, for exempting from
The interactive targeted drug of epidemic disease cells against tumor cells, is expected to applied immunology principle and method, improves exempting from for tumour cell
The sensitiveness of epidemic focus and pairing effect cell killing, excitation and enhancing antitumor immunity of organism response, cooperate with body immune system,
So as to suppress the growth, transfer and recurrence of tumour.
LSECtin (Liver Sinusoidal Endothelial Cells lectin) is II type transmembrane glycoprotein, position
It is the newcomer of c-type lectin family in mankind 19p13.3.
BTN3A2 (Butyrophilin subfamily 3member A2) and BTN3A3 (Butyrophilin
3 member A3 of subfamily) it is I type transmembrane glycoprotein, it is the member of B7 superfamilies positioned at mankind 6p22.2.
The content of the invention
It is an object of the present invention to provide the new application for the material for suppressing BTN3A expression and/or activity.
The present invention provides the material for suppressing BTN3A expression and/or activity to prepare with least one in following (1)-(5)
Application in the product of kind function:
(1) treatment and/or pre- preventing tumor;
(2) growth of tumour cell is suppressed;
(3) maintenance or promotion of tumour cell dryness are suppressed;
(4) expression of tumour cell dryness correlated characteristic molecule is suppressed;
(5) inside tumor cells STAT3 phosphorylations are suppressed;
The BTN3A is following a1) or a2):
a1)BTN3A3;
A2) BTN3A2 and BTN3A3.
In above application, the material of the suppression BTN3A expression and/or activity is following any:Disturb BTN3A2 and
The RNA molecule of BTN3A3 expression, anti-LSECtin antibody, LSECtin micromolecular inhibitors, LSECtin soluble proteins, interference
The RNA molecule of LSECtin expression, anti-BTN3A2 antibody, BTN3A2 micromolecular inhibitors, BTN3A2 soluble proteins, interference
RNA molecule, anti-BTN3A3 antibody, BTN3A3 micromolecular inhibitors, BTN3A3 soluble proteins and the interference of BTN3A2 expression
The RNA molecule of BTN3A3 expression.
In above application, what the RNA molecule of the interference BTN3A2 and BTN3A3 expression and the interference BTN3A3 were expressed
RNA molecule is following b1)-b4):
B1) the shRNA molecule shown in sequence 4;
B2) sequence 4 is deleted or increases or change one or several nucleotide, and with the nucleotide of 4 identical function of sequence;
B3) the shRNA molecule shown in sequence 5;
B4) sequence 5 is deleted or increases or change one or several nucleotide, and with the nucleotide of 5 identical function of sequence.
In above application, the tumour cell dryness correlated characteristic molecule for Oct4 genes and/or Nanog genes and/or
Sox genes.
In above application, the growth for suppressing tumour cell is embodied in the tumor formation rate for reducing tumour cell and/or reduction
The volume of tumour cell.
In above application, the product is medicine.
In above application, the tumour is following c1) or c2):
C1) the tumour of BTN3A3 expression;
C2 the tumour of under) LSECtin is stimulated and BTN3A3 expression;
The tumour is specially breast cancer, liver cancer, stomach cancer, colon cancer, lung cancer, giant cell tumor of bone, kidney, carcinoma of parotid gland.
It is a further object to provide a kind of product.
The active ingredient of product provided by the invention is expressed for suppression BTN3A and/or the material of activity, the use of the product
Way is at least one of following (1)-(5):
(1) treatment and/or pre- preventing tumor;
(2) growth of tumour cell is suppressed;
(3) maintenance or promotion of tumour cell dryness are suppressed;
(4) expression of tumour cell dryness correlated characteristic molecule is suppressed;
(5) inside tumor cells STAT3 phosphorylations are suppressed;
The BTN3A is following a1) or a2):
a1)BTN3A3;
A2) BTN3A2 and BTN3A3.
In the said goods, the material of the suppression BTN3A expression and/or activity is following any:Disturb BTN3A2 and
The RNA molecule of BTN3A3 expression, anti-LSECtin antibody, LSECtin micromolecular inhibitors, LSECtin soluble proteins, interference
The RNA molecule of LSECtin expression, anti-BTN3A2 antibody, BTN3A2 micromolecular inhibitors, BTN3A2 soluble proteins, interference
RNA molecule, anti-BTN3A3 antibody, BTN3A3 micromolecular inhibitors, BTN3A3 soluble proteins and the interference of BTN3A2 expression
The RNA molecule of BTN3A3 expression.
In the said goods, what the RNA molecule of the interference BTN3A2 and BTN3A3 expression and the interference BTN3A3 were expressed
RNA molecule is following b1)-b4):
B1) the shRNA molecule shown in sequence 4;
B2) sequence 4 is deleted or increases or change one or several nucleotide, and with the nucleotide of 4 identical function of sequence;
B3) the shRNA molecule shown in sequence 5;
B4) sequence 5 is deleted or increases or change one or several nucleotide, and with the nucleotide of 5 identical function of sequence.
In the said goods, the tumour cell dryness correlated characteristic molecule for Oct4 genes and/or Nanog genes and/or
Sox genes.
In the said goods, the growth for suppressing tumour cell is embodied in the tumor formation rate for reducing tumour cell and/or reduction
The volume of tumour cell.
In the said goods, the product is medicine.
In the said goods, the tumour is following c1) or c2):
C1) the tumour of BTN3A3 expression;
C2 the tumour of under) LSECtin is stimulated and BTN3A3 expression;
The tumour is specially breast cancer, liver cancer, stomach cancer, colon cancer, lung cancer, giant cell tumor of bone, kidney, carcinoma of parotid gland.
Final object of the present invention is to provide the new application of BTN3A2 and/or BTN3A3 as target spot.
The present invention provides applications of the BTN3A2 and/or BTN3A3 as target spot in immunotherapy of tumors.
Present invention also offers BTN3A2 and/or BTN3A3 as target spot develop or design immunotherapy of tumors medicine in
Application.
In above application, the product is medicine.
In above application, the tumour is following c1) or c2):
C1) the tumour of BTN3A3 expression;
C2 the tumour of under) LSECtin is stimulated and BTN3A3 expression;
The tumour is specially breast cancer, liver cancer, stomach cancer, colon cancer, lung cancer, giant cell tumor of bone, kidney, carcinoma of parotid gland.
In above application or product,
The LSECtin for it is following 1) or 2):
1) protein being made of the amino acid sequence shown in sequence in sequence table 1;
2) amino acid sequence of sequence 1 is passed through to the substitution and/or missing and/or addition of one or several amino acid residues
And the protein as derived from sequence 1 with identical function.
The BTN3A2 for it is following 1) or 2):
1) protein being made of the amino acid sequence shown in sequence in sequence table 2;
2) amino acid sequence of sequence 2 is passed through to the substitution and/or missing and/or addition of one or several amino acid residues
And the protein as derived from sequence 2 with identical function;
The BTN3A3 for it is following 1) or 2):
1) protein being made of the amino acid sequence shown in sequence in sequence table 3;
2) amino acid sequence of sequence 3 is passed through to the substitution and/or missing and/or addition of one or several amino acid residues
And the protein as derived from sequence 3 with identical function.
The present invention is experimentally confirmed:LSECtin, BTN3A2 and BNT3A3 are by promoting the maintenance of tumour cell dryness to promote
Into tumor progression, it is embodied in and promotes tumour cell ball to be formed, in the expression of dryness transcription factor and mouse tumor model
Promotion to tumor progression;Tumor progression can effectively be slowed down by suppressing the interaction of LSECtin and BTN3A2 and BTN3A3, be had
Body, which is embodied in reduce Tumor incidence and slow down gross tumor volume, to be increased.
Brief description of the drawings
Fig. 1 is clinical sample tumor cells expression BTN3A3.Fig. 1 (a) is in flow cytometer detection breast cancer patients tumor tissues
Tumor cells expression is horizontal;Fig. 1 (b) is that tumor cells expression is horizontal in flow cytometer detection lung cancer patient tumor tissues;Fig. 1 (c) is
Tumor cells expression is horizontal in flow cytometer detection colon cancer patient tumor tissues;Fig. 1 (d) swells for flow cytometer detection giant cell tumor of bone patient
Tumor cells expression is horizontal in tumor tissue;Fig. 1 (e) is that tumor cells expression is horizontal in flow cytometer detection kidney patient's tumor tissues;
Fig. 1 (f) is that tumor cells expression is horizontal in flow cytometer detection carcinoma of parotid gland patient's tumor tissues.
Fig. 2 expresses BTN3A3 for kinds of tumor cells system.Fig. 2 (a) expresses BTN3A3 for a variety of breast cancer cell lines;Fig. 2
(b) BTN3A3 is expressed for a variety of liver cancer cell lines;Fig. 2 (c) expresses BTN3A3 for human melanoma cell line;Fig. 2 (d) is a variety of
Gastric carcinoma cell lines express BTN3A3;Fig. 2 (e) expresses BTN3A3 for colon carcinoma cell line.
Fig. 3 is expression of the BTN3A2 and BTN3A3 on breast cancer cell.Fig. 3 (a) shows that breast cancer is thin for qPCR detections
Born of the same parents are expression BTN3A2 and BTN3A3;Fig. 3 (b) shows that BTN3A is expressed in breast cancer cell surface for fluidic cell;Fig. 3 (c) is
Cellular immunofluorescence detects BTN3A3 and is positioned in breast cancer cell skin covering of the surface.
Fig. 4 is that the BTN3A3 of tumor cells expression promotes tumour to be formed.Fig. 4 (a) is the mRNA water of BTN3A3 and BTN3A2
Flat expression quantity detection;The protein expression amount that Fig. 4 (b) is BTN3A3 detects;Fig. 4 (c) is 231- in people-model in nude mice
NC and 231-sh4 are into knurl volume vs;231-NC is contrasted with 231-sh4 tumor formation rates in Fig. 4 (d) people-model in nude mice.
Fig. 5 is that there are direct and specific interaction by the BTN3A3 of LSECtin and tumor cells expression.;Fig. 5 (a)
For the BTN3A3 of people source LSECtin and tumor cells expression, there are direct and specific interaction;Fig. 5 (b) is mouse source
There are direct and specific interaction by the BTN3A3 of LSECtin and tumor cells expression.
Fig. 6 is LSECtin by promoting tumour cell dryness with the BTN3A3 of tumor cells expression interactions.Fig. 6 (a)
Promote tumour cell MDA-MB-231 ball Forming abilities with Fig. 6 (b) for LSECtin/BTN3A3;Fig. 6 (c) for LSECtin with
BTN3A3 interactions promote the up-regulation of tumour cell dryness transcription factor.
Fig. 7 be the BTN3A3 interactions of LSECtin and tumor cells expression promote in tumour cell STAT3 phosphorylations into
And tumour cell dryness is promoted to maintain result.Fig. 7 (a) promotes tumour cell STAT3 phosphorylations for LSECtin/BTN3A3, but right
Other STAT molecules are without activation;Fig. 7 (b) can block LSECtin/BTN3A3 to promote tumour thin to suppress STAT3 inhibitor
Born of the same parents' balling-up effect.
Embodiment
Experimental method used in following embodiments is conventional method unless otherwise specified.
The materials, reagents and the like used in the following examples, is commercially available unless otherwise specified.
Quantitative test in following embodiments, is respectively provided with three repeated experiments, and results are averaged.
RNA extracts kits, cDNA reverse transcription reagent box (A3500) and Mix (A6001) in following embodiments are
The product of Promega companies.
Cell counting count board (145-0011) in following embodiments is the product of Biorad companies.
CCK8 Cell counting Kits (CK04) in following embodiments are the products of eastern Renhua scientific & technical corporation.
LSECtin (QT01034446), BTN3A2 (QT00060039) and BTN3A3 in following embodiments
(QT00060039) qPCR primers are the synthesis of Qiagen companies.
4-6 weeks Female nude mice in following embodiments is the product for tieing up company of tonneau China.
Clostridiopetidase A IV (C5138) in following embodiments is the product of Sigma companies.
DNase I in following embodiments is the product of Xi Meijie companies.
Confining liquid in following embodiments:Solvent is water, solute Na2HPO4、KH2PO4, NaCl and skim milk;Solute
Na2HPO4、KH2PO4, the concentration of NaCl and skim milk in confining liquid be respectively 0.02M, 0.0015M, 0.14M and 3% (matter
Measure percentage composition).
Human breast cancer cell MDA-MB-231 in following embodiments is purchased from National Laboratory cellular resources shared platform, and presses
The training method culture provided according to the platform.The condition of culture of human breast cancer cell line MDA-MB-231 is to contain 10% tire
Cow's serum (Gibico, article No.:RPMI 1640 culture medium (Thermofish, article No. 10100-147-FBS):
SH30809.01B 37 DEG C in), 5%CO2It is incubated.
Mouse anti human LSECtin antibody CCB059 in following embodiments is in document " Zhao D, Han X, Zheng X, et
al.Correction:The Myeloid LSECtin Is a DAP12-Coupled Receptor That Is Crucial
for Inflammatory Response Induced by Ebola Virus Glycoprotein[J].PLoS
Pathogens, mistake disclosed in 2016,12 (3) ", the public can obtain from Military Medical Science Institute.
Rabbit anti-mouse LSECtin in following embodiments resists in document " Xu F, Liu J, Liu D, et more
al.LSECtin expressed on melanoma cells promotes tumor progression by
inhibiting antitumor T-cell responses[J].Cancer research,2014,74(13):3418-
Mistake disclosed in 3428. ", the public can obtain from Military Medical Science Institute.
Mouse source LSECtin-Fc in following embodiments is in document " Tang L, Yang J, Tang X, et al.The DC-
SIGN family member LSECtin is a novel ligand of CD44on activated T cells[J]
.European journal of immunology,2010,40(4):Mistake disclosed in 1185-1191. ", the public can cure from military affairs
Subject institute obtains.
Embodiment 1, various clinical sample tumor cells expression BTN3A2 and BTN3A3
First, the separation of clinical sample tumour cell
(1) preparation of digestive juice:By 1640 culture mediums (Hyclone companies, SH30809), the 20mg clostridiopetidase As IV of 20ml
And 1mg DNase I are mixed, digestive juice, 0.45 μm of membrane filtration are obtained.
(2) fresh clinical patient tumor tissues are taken respectively, after shredding, are put into the digestive juice of step (1) preparation, are swollen
Knurl digestive juice, 37 DEG C of digestion 40min.
(3) with 70 μm of strainer filtering tumour digestive juice, 250g centrifugations 10min.
(4) tumour cell 3 times in tumour digestive juice is cleaned with 1640 culture mediums, tumour is obtained by airflow classification respectively
Cell enrichment subgroup:Comprise the following steps that:Living cells group is passed sequentially through into SSC-H/FSC-W and SSC-W/FSC-H and removes adhesion
Cell, SSC-A and FSC-A remove cell fragment, CD45- obtains tumor cell enrichment subgroup, and resists by using anti-CD277
Body (antibody identifies BTN3A1, BTN3A2, BTN3A3 of form membrane at the same time) carries out BTN3A detection of expression.
2nd, in breast cancer patients tumor tissues tumour cell BTN3A expressions detection
According to the description in above-mentioned one, tumour cell BTN3A expressions in breast cancer patients tumor tissues are examined
Survey.
As a result as shown in Fig. 1 (a):With CD45-The breast cancer tumor cells surface expression BTN3A of definition.
3rd, in lung cancer patient tumor tissues tumour cell BTN3A expressions detection
According to the description in above-mentioned one, tumour cell BTN3A expressions in lung cancer patient tumor tissues are detected.
As a result as shown in Fig. 1 (b):With CD45-The lung cancer tumor cellular portions surface expression BTN3A of definition.
4th, in colon cancer patient tumor tissues tumour cell BTN3A expressions detection
According to the description in above-mentioned one, tumour cell BTN3A expressions in colon cancer patient tumor tissues are examined
Survey.
As a result as shown in Fig. 1 (c):With CD45-The colon cancer tumours cellular portions surface expression BTN3A of definition.
5th, in giant cell tumor of bone patient tumor tissues tumour cell BTN3A expressions detection
According to the description in above-mentioned one, to tumour cell BTN3A expressions in giant cell tumor of bone patient's tumor tissues into
Row detection.
As a result as shown in Fig. 1 (d):With CD45-The giant cell tumor of bone tumour cell part surface expression BTN3A of definition.
6th, in kidney patient tumor tissues tumour cell BTN3A expressions detection
According to the description in above-mentioned one, tumour cell BTN3A expressions in kidney patient's tumor tissues are detected.
As a result as shown in Fig. 1 (e):With CD45-The renal cancer tumor cellular portions surface expression BTN3A of definition.
7th, in carcinoma of parotid gland patient tumor tissues tumour cell BTN3A expressions detection
According to the description in above-mentioned one, tumour cell BTN3A expressions in carcinoma of parotid gland patient's tumor tissues are examined
Survey.
As a result as shown in Fig. 1 (f):With CD45-The carcinoma of parotid gland tumour cell part surface expression BTN3A of definition.
Embodiment 2, kinds of tumor cells system expression BTN3A3
1st, the culture of tumor cell line
Cultivate following breast cancer cell line:MCF7(3111C0001CCC000013)、ZR75-1
(3111C0001CCC000090)、BT474(3111C0001CCC000129)、T47D(3111C0001CCC000265)、MDA-
MB-453(3111C0001CCC000016)、SKBR3(3111C0001CCC000085)、MDA-MB-468
(3111C0001CCC000249)、MDA-MB-436(3111C0001CCC000352);MDA-MB-231
(3111C0001CCC000013);Liver cancer cell lines:BEL-7402(3131C0001000700010)、HepG2
(3111C0001CCC000035)、HCC-LM3(3142C0001000000316)、HHCC(3111C0002000000069)、
Hep3B(3111C0001CCC000376)、QGY7701(3131C0001000700042)、SMCC7721
(3111C0001CCC000087)、Huh7(3131C0001000700182);K-1735:A875
(3111C0001CCC000094)、A375(3131C0001000700004);Gastric carcinoma cell lines:MKN28
(3111C0001CCC000482)、NCI-N87(3111C0001CCC000481)、MGC-803(3111C0001CCC000227)、
SGC-7901(3131C0001000700046);Colon carcinoma cell line:LOVO(3111C0001CCC000164)、SW480
(3142C0001000000064)、LS174T(3111C0001CCC000248)、DLD-1(3131C0001000700134).On
State cell and be purchased from National Laboratory cellular resources shared platform.Above-mentioned cell culture condition is by " National Laboratory cellular resources are shared
The method culture of platform " query site.
2nd, above-mentioned each cell line is cracked respectively with RIPA lysates (Thermofisher, 89901), is obtained respectively
Cell pyrolysis liquid is obtained, and Western Blot detections are carried out to cell pyrolysis liquid respectively, passes through anti-BTN3A3 antibody
(Sigma, HPA007904) detects BTN3A3 expressions.
As a result as shown in Fig. 2 (a)-(e):It can be seen from the figure that kinds of tumor cells system expresses BTN3A3.
The expression of embodiment 3, BTN3A2 and BTN3A3 on breast cancer cell
First, qPCR detects the expression that breast cancer cell fastens BTN3A2 and BTN3A3
1st, the extraction of RNA and the reverse transcription of cDNA
Following each breast cancer cell is extracted using RNA extracts kits:MCF7、ZR75-1、BT474、T47D、SKBR3、
The RNA of MDA-MB-468, MDA-MB-231, MDA-MB-436;CDNA is synthesized according to the method for cDNA synthetic agent box.
2nd, qPCR detects breast cancer cell and fastens BTN3A3 expressions
The cDNA obtained using step 1 is expanded as template using real time fluorescent quantitative nucleic acid amplification detecting system (qPCR)
BTN3A2, BTN3A3 and GAPDH, and pass through software analysis BTN3A2, BTN3A3 relative expression quantities.Above-mentioned BTN3A2, BTN3A3
And GAPDH primers are purchased from Qiagen companies.
As a result as shown in Fig. 3 (a).QPCR testing results show:Breast cancer cell MDA-MB-231, MDA-MB-468,
The upper high expression BTN3A2 and BTN3A3 of MDA-MB-436.
2nd, fluidic cell shows BTN3A developed by molecule in breast cancer cell surface
With anti-CD277 antibody (antibody identifies BTN3A1, BTN3A2, BTN3A3 of form membrane at the same time) to following breast
Gland cell system:MCF7, ZR75-1, BT474, MDA-MB-468, MDA-MB-231, MDA-MB-436 carry out flow cytometer detection.Tool
Body step is as follows:Experimental group is with 1 × PBS with 1:50 volume ratios dilution anti-CD277 antibody (eBioscience, 14-2779),
Control group is with 1 × PBS with 1:50 volume ratios dilution isotype control Ab (eBioscience, 14-4714-82), 4 DEG C of incubations
30min.After washing cell 3 times with 1 × PBS, supernatant is abandoned.With 1:50 volume ratios dilute sheep anti-Mouse PE mark fluorescent secondary antibodies
(Biolegend, 405307) marks cell, 4 DEG C of incubation 30min.After washing cell 3 times with 1 × PBS, supernatant is abandoned, with 300 μ l
PBS carries out flow cytometer detection after being resuspended.
As a result as shown in Fig. 3 (b), as can be seen from the figure:BTN3A is expressed in breast cancer cell MDA-MB-468, MDA-
The surface of MB-231 and MDA-MB-436.
3rd, cellular immunofluorescence detection BTN3A3 is positioned in breast cancer cell skin covering of the surface
The MDA-MB-231 cells under cultivation conditions are collected, is washed three times with PBS, washes away unnecessary serum.Dilute the permeable membrane of 10X
Liquid (being up to section, 421002) into 1 × working solution.Fixed cell is resuspended with permeable membrane liquid, 350g centrifugation 10min, abandon supernatant, repeat
The step is once.The cell after fixed rupture of membranes is resuspended in 100ul permeable membranes liquid, with permeable membrane liquid with 1:The diluted anti-of 200 volume ratios
BTN3A3 antibody (Sigma, HPA007904), 4 DEG C of incubation 30min.After washing cell 3 times with permeable membrane liquid, supernatant is abandoned.Add with body
Product ratio 1:200 diluted rabbit TRITC fluorescence antibodies (Zhong Shan Golden Bridge, ZF-0318), 4 DEG C of lucifuges are incubated 30min.Washed with permeable membrane liquid
Cell three times after, cell is put into glass slide, fluorescence microscopy Microscopic observation BTN3A3 expressions.
As a result as shown in Fig. 3 (c), as can be seen from the figure:MDA-MB-231 cells express BTN3A3, and are primarily targeted for
Cell membrane.
Embodiment 4, the BTN3A2 of tumor cells expression and BTN3A3 promote tumour to be formed
Utilize the influence of 231-NC cells and the BTN3A3 of 231-sh4 cells verification tumour expression to tumor progression.Specifically
Step is as follows:
1st, the structure of the human breast cancer cell MDA-MB-231 of low BTN3A3 is struck
231-sh3 cells and 231-sh4 cells are stable enhanced green fluorescent protein and strike people's mammary gland of low BTN3A3
Cancer cell MDA-MB-231,231-NC cell is the human breast cancer cell MDA-MB-231 for stablizing enhanced green fluorescent protein.Tool
Body construction step is as follows
(1) entrust Suzhou Ji Ma companies complete strike low BTN3A3 the structure of sh expression plasmids and the packaging of slow virus with it is pure
The step of change.Sh RNA sequences are as follows:sh3:GCCACAGATGGATCTCATATC (sequence 4);sh4:
CCCTTCTGCAACAACCAATCA (sequence 5);NC (negative control sequence):TTCTCCGAACGTGTCACGTTTC.
(2) using slow virus respectively by sh3 expression plasmids transfection aim cell (the human breast cancer cell MDA-MB- of structure
231), and by fluorescin screened, obtain striking the stable cell lines 231-sh3 of low BTN3A3.
Using slow virus respectively by sh4 expression plasmids transfection aim cell (the human breast cancer cell MDA-MB- of structure
231), and by fluorescin screened, obtain striking the stable cell lines 231-sh4 of low BTN3A3.
The NC expression plasmids of structure are transfected into aim cell (human breast cancer cell MDA-MB-231) respectively using slow virus,
And screened by fluorescin, obtain control cell lines 231-NC.
Above-mentioned transfection comprises the following steps that:When 18-24 is small before virus transfection, by attached cell with 1 × 105A/hole paving
Into 24 orifice plates.It is 2 × 10 to make quantity of the cell in slow-virus transfection5MOI/ holes or so.Second day, with containing 6 μ g/ml
The 2ml fresh cultures of polybrene (Suzhou Ji Ma companies) replace former culture medium, add appropriate viral suspension.Continue to cultivate
24 it is small when, with fresh culture replace contain virulent culture medium.Visible obvious luciferase expression after when virus infection 48 is small, 72 is small
When after it is more obvious.Expand culture one week, the cell with GFP is obtained by airflow classification.
(3) the mRNA level in-site expression quantity detection of BTN3A3 and BTN3A2
10 are collected respectively5A 231-sh4 cells and 231-NC control cells, using qPCR respectively to 231-sh4 cells and
The BTN3A1 of 231-NC control cells, BTN3A2, BTN3A3mRNA horizontal expressions are detected.Comprise the following steps that:According to examination
Method shown in agent box specification carries out RNA extractions and reverse transcription, and the cDNA of acquisition, recycles qPCR primers to carry out qPCR.Wherein,
The small extraction reagent kits of RNA (74034) are purchased from Qiagen companies.RNA reverse transcription reagent box (Promega) is purchased from Promega companies.
BTN3A1 (QF00264803), BTN3A2 (QT00060039), BTN3A3 (QF00264803) gene qPCR primers are purchased from
Qiagen companies.
Shown in testing result such as Fig. 4 (a), compared with control cell 231-NC, the stable cell lines 231- of low BTN3A3 is struck
In sh4, the relative expression quantity of BTN3A2 and BTN3A3 are below 0.4, illustrate to strike in the stable cell lines 231-sh4 of low BTN3A3
BTN3A2 and BTN3A3 expressions substantially reduce.
(4) the protein expression amount detection of BTN3A3
10 are collected respectively5A 231-sh3 cells, 231-sh4 cells and 231-NC control cells, to 231-sh3 cells,
231-sh4 cells and the BTN3A3 protein expressions of 231-NC control cells are detected.Comprise the following steps that:Split with RIPA
Solution liquid (Thermofisher, 89901) is respectively cracked above-mentioned each cell line, obtains cell pyrolysis liquid respectively, and divide
It is other that Western Blot detections are carried out to cell pyrolysis liquid, detected by anti-BTN3A3 antibody (Sigma, HPA007904)
BTN3A3 expressions, specific method reference antibody specification.
As a result as shown in Fig. 4 (b), compared with control cell 231-NC, strike low BTN3A3 stable cell lines 231-sh3 and
Striking BTN3A3 expressions in the stable cell lines 231-sh4 of low BTN3A3 substantially reduces.
2nd, respectively by control cell 231-NC and 231-sh4 cell with a 1000 cells/plantation nude mice mammary gland fat in situ
Fat pad.After inoculating cell, the 8th day starts to observe, and observes weekly once afterwards, mouse tumor is measured respectively using vernier caliper
Major diameter a and minor axis b, and calculate gross tumor volume and tumor formation rate.Gross tumor volume calculation formula is 0.5*ab2.When 6 weeks, place
Dead mouse.
Shown in the testing result of gross tumor volume such as Fig. 4 (c), mouse is the 0th, 1,2,3,4,5,6 after 231-NC cells are inoculated with
All gross tumor volumes are respectively 0.000 ± 0.000,3.398 ± 5.829,10.627 ± 10.152,32.637 ± 20.258,
60.116 ± 24.670,158.550 ± 59.933 and 331.362 ± 100.745 (unit mm3);Mouse is in inoculation 231-sh4
The 0th after cell, 1,2,3,4,5,6 weeks gross tumor volumes be respectively 0.000 ± 0.000,0.000 ± 0.000,4.068 ± 6.957,
14.460 ± 20.532,13.208 ± 17.609,36.183 ± 48.657 and 96.543 ± 127.005 (unit mm3);
Shown in the testing result of tumor formation rate such as Fig. 4 (d), the tumor formation rates of control cell 231-NC group mouse is apparently higher than 231-
Sh4 groups.
The above results show:After striking low BTN3A2 and BTN3A3, tumor formation rate of the breast cancer cell in nude mouse, into knurl
Volume is decreased obviously.Illustrate that BTN3A2 and BTN3A3 promotes tumour to be formed.
There are direct and specific interaction by embodiment 5, LSECtin and BTN3A2 and BTN3A3
There are direct and special interaction with BTN3A2 and BTN3A3 by adhesion experiment verification LSECtin
1st, BTN3A1, the structure of the carrier of BTN3A2, BTN3A3 are overexpressed
BTN3A1 sequences (sequence 6), BTN3A2 sequences (sequence 7), BTN3A3 sequences (sequence 8) are replaced respectively
DNA fragmentation between I restriction enzyme site of Nde I and Xho of pIRES2-EGFP carriers (Clotech, 6029-1), is expressed respectively
The carrier pIRES2-EGFP-BTN3A1 of BTN3A1, the pIRES2-EGFP-BTN3A2 for expressing BTN3A2, express BTN3A3's
pIRES2-EGFP-BTN3A3。
2nd, the carrier pIRES2-EGFP-BTN3A1 of BTN3A1 will be expressed respectively, expresses the pIRES2-EGFP- of BTN3A2
BTN3A2, (country is real for pIRES2-EGFP-BTN3A3 and empty carrier pIRES2-EGFP transfection the BT474 cells of expression BTN3A3
Test cellular resources shared platform, 3111C0001CCC000129), after transfecting 36h, respectively obtain the cell for being overexpressed BTN3A1
BT474-BTN3A1, be overexpressed BTN3A2 cell BT474-BTN3A2, be overexpressed BTN3A3 cell BT474-BTN3A3 and
It is overexpressed the cell BT474-EGFP of empty carrier.
3rd, each cell that collection step 2 obtains is digested, respectively employment source LSECtin albumen (R&D, 2947-CL) and mouse
Source LSECtin-Fc albumen and above-mentioned each cell adherence, and detect people source with mouse anti human LSECtin antibody CCB059
LSECtin adhesion rates, with anti-IgG (Biolegend, 405307) detection mouse source LSECtin adhesion rates, pass through flow cytometer detection
Adhesion percentage.Adhesion experiment specific steps reference literature " Tang L, Yang J, Tang X, et al.The DC-SIGN
family member LSECtin is a novel ligand of CD44 on activated T cells[J]
.European journal of immunology,2010,40(4):1185-1191. " in method.
Adhesion experiment verify LSECtin and BTN3A3 there are result such as Fig. 5 (a) of direct and specific interaction and
Shown in Fig. 5 (b).Wherein, shown in people source LSECtin adhesion results such as Fig. 5 (a), LSECtin and the cell for being overexpressed empty carrier
BT474-EGFP does not adhere to (adhesion rate 3.579%), and the cell BT474-BTN3A1 with being overexpressed BTN3A1 does not adhere to (adhesion
Rate is 0.775%) the weak adhesions (adhesion rate 42.33%) of cell BT474-BTN3A2 with being overexpressed BTN3A2, with overexpression
The cell BT474-BTN3A3 of BTN3A3 is adhered to by force (adhesion rate 57.587%).Mouse source LSECtin-Fc adhesion results such as Fig. 5
(b) shown in, LSECtin does not adhere to (adhesion rate 0.967%), with being overexpressed with being overexpressed the cell BT474-EGFP of empty carrier
The cell BT474-BTN3A1 of BTN3A1 does not adhere to (adhesion rate 1.598%), the cell BT474- with being overexpressed BTN3A2
BTN3A2 does not adhere to (adhesion rate 6.61%), and (adhesion rate 27.345%) is adhered to BT474-BTN3A3.
The above results illustrate, the BTN3A3 of people source and mouse source LSECtin and human tumor cells surface expression exist directly and
There are strong interaction by the BTN3A3 of special strong interaction, people source LSECtin and human tumor cells surface expression.
Embodiment 6, LSECtin and BTN3A2 and BTN3A3 interactions promote the maintenance of tumour cell dryness
First, ball, which forms experiment, proves that LSECtin and BTN3A2 and BTN3A3 interactions promote the dimension of tumour cell dryness
Hold
The present embodiment forms experiment by ball proves that LSECtin and BTN3A2 and BTN3A3 interactions promote tumour cell
The maintenance of dryness.Comprise the following steps that:
1st, 2 in 231-sh3 cells, 231-sh4 cells and 231-NC cells, and 5 step 2 of embodiment are obtained respectively
The cell BT474-BTN3A1 of the overexpression BTN3A1 obtained, the cell BT474-BTN3A2 for being overexpressed BTN3A2, be overexpressed
Single cell suspension is made in the cell BT474-BTN3A3 of BTN3A3 and the cell BT474-EGFP of overexpression empty carrier, and the first generation is thin
Born of the same parents are passed on 1000/mL bed boards with 20,000/mL bed boards.
2nd, respectively by above-mentioned each cell, B27 (Life, 17504044), bFGF (Sigam, SRP2092), EGF
(Sigma, E9644), insulin (Sigma, I3536), heparin (sigma, 1235853) and DMEM/F12 serum free mediums mix
After even, cultivating system is respectively obtained, concentration of each component in cultivating system is:B27(10ng/ml)、bFGF(20ng/
Ml), EGF (20ng/ml), insulin (5 μ g/ml), heparin (4 μ g/ml), after cultivating 7-10 days, calculated diameter is more than 75 μm
Number of spheres is simultaneously taken pictures.
3rd, sphere is collected by centrifugation in 800rpm, and pancreatin (Gibico, 25300120) digestion, 40 μm of screen filtrations, carry out secondary
Sphere forms experiment.
4th, adding the LSECitn that concentration is 100ng/ml into above-mentioned each cultivating system respectively stimulates tumour cell, point
The post-stimulatory each cells of LSECitn are not obtained.
As a result as shown in Fig. 6 (a) and Fig. 6 (b), under the LSECtin irritaiting concentrations of 100ng, LSECtin can promote pair
Photo cell 231-NC cell balls are formed;But it cannot promote to strike the 231-sh3 cells and 231-sh4 cells of low BTN3A2 and BTN3A3
Ball formed.Under the LSECtin irritaiting concentrations of 100ng, LSECtin cannot promote to be overexpressed the cell BT474- of empty carrier
The ball of EGFP is formed;But it can promote to be overexpressed the cell BT474-BTN3A2 of BTN3A2, be overexpressed the cell of BTN3A3
The ball of BT474-BTN3A3 is formed.
2nd, the detection of dryness characteristic molecular expression
4 balls obtained in collection step one form 231-sh4 cells and 231-NC cells in experiment, are examined by qPCR
Survey the expression change of tumor of breast dryness correlated characteristic molecule OCT4, NANOG, SOX2.DC-SIGN represents negative control,
Control is unused LSECtin stimulations group, and 231-sh4 is the cell for striking low BTN3A3, and 231-NC is control cell.Primer sequence
Row are as follows:OCT4:Up-GCTCGAGAAGGATGTGGTCC;Down-GTTGTGCATAGTCGCTGCT;NANOG:Up-
TCTGGACACTGGCTGAATCCT;Down-CGCTGATTAGGCTCCAACCAT;SOX2:Up-
GCTCGCAGACCTACATGAAC;Down-GGGAGGAAGAGGTAACCACA.
As a result as shown in Fig. 6 (c), under the LSECtin irritaiting concentrations of 100ng, LSECtin can promote dryness is crucial to turn
Record the expression of the factor Oct4, Nanog and Sox;But the promotion effect then cannot after BTN3A3 is knocked out.
The above results illustrate that LSECtin and BTN3A2 and BTN3A3 interactions promote tumor progression and promote tumour thin
The maintenance of born of the same parents' dryness.
Embodiment 7, LSECtin and BTN3A2 and BTN3A3 interactions promote tumor progression to rely in activation tumour cell
STAT3 phosphorylations
First, LSECtin stimulates the breast cancer cell STAT3 phosphorylations of expression BTN3A3
4 of step 1 in embodiment 6 ball stimulated through LSECtin obtained is collected respectively forms sample:Strike low BTN3A3
231-sh3 cells (LSECitn-231-sh3), strike 231-sh4 cells (LSECitn-231-sh4), the cell of low BTN3A3
The ball stimulated without LSECtin obtained in the 3 of 6 step 1 of 231-NC (LSECitn-231-NC) and embodiment forms sample:
Strike the 231-sh3 cells (231-sh3) of low BTN3A3, strike 231-sh4 cells (231-sh4), the cell 231-NC of low BTN3A3
(231-NC).Digested using pancreatin, 4 DEG C, after 1000rmp centrifugations, abandon supernatant, collect cell, and cell three is washed by PBS
It is secondary.30min is cracked by RIPA lysates on ice, 12,000rmp centrifugations, take supernatant, obtain cell pyrolysis liquid.Pass through Stat
Antibody Sampler Kit kits (Cell signaling technology, 9939) Western Blot detections are split
The background level of STAT1, STAT3, STAT5, STAT6 in liquid are solved, passes through Phospho-Stat Antibody Sampler Kit
The phosphorus of STAT1, STAT3, STAT5, STAT6 in kit (Cell signaling technology, 9914) detection lysate
Acidifying is horizontal.Specific detection method is with reference to the specification in kit.
As a result as shown in Fig. 7 (a), under LSECtin is stimulated, the p- of the 231-NC cells of normal expression BTN3A2 and BTN3A3
The horizontal obvious up-regulations of STAT3;But strike the 231-sh3 cells (LSECitn-231-sh3) of low BTN3A2 and BTN3A3, strike it is low
In the 231-sh4 cells (LSECitn-231-sh4) of BTN3A2 and BTN3A3, LSECtin cannot be stimulated in p-STAT3 levels
Adjust;But regardless of whether striking low BTN3A3, other molecule STAT1, STAT5, STAT6 phosphorylation levels of STAT families are made without up-regulation
With.
The above results illustrate that LSECtin can stimulate the horizontal up-regulations of p-STAT3 by interacting with BTN3A3.
2nd, LSECtin promotes the breast cancer cell ball of expression BTN3A2 and BTN3A3 to form dependence STAT3 phosphorylations
The ball obtained in the 4 of 6 step 1 of embodiment is collected respectively forms sample:Strike the cell 231-sh3 of low BTN3A3, strike
The cell 231-sh4 of the low BTN3A3 and cell 231-NC for striking low BTN3A3, and the 3rd day after sample is collected adds STAT3
Inhibitor (selleck, S1155), the tenth day detection ball quantity of formation.
As a result as shown in Fig. 7 (b), after adding STAT3 inhibitor, LSECtin promotes normal expression BTN3A2 and BTN3A3
The ball Forming abilities of 231-NC cells substantially reduce;Striking 231-sh3 the and 231-sh4 cells of low BTN3A2 and BTN3A3
In, add STAT3 inhibitor and cause LSECtin to promote ball formation effect to be wholly absent.
The above results illustrate that LSECtin and BTN3A2 and the BTN3A3 interaction of breast cancer cell expression promote tumour
Process depends on the STAT3 phosphorylation levels of cell interior.
Sequence table
<110>In INST OF EMISSION & RADIATION M's Beijing proteome research
The heart
<120>A kind of target spot of oncotherapy and its application
<160>8
<210>1
<211>293
<212>PRT
<213>Artificial sequence
<220>
<223>
<400>1
Met Asp Thr Thr Arg Tyr Ser Lys Trp Gly Gly Ser Ser Glu Glu Val
1 5 10 15
Pro Gly Gly Pro Trp Gly Arg Trp Val His Trp Ser Arg Arg Pro Leu
20 25 30
Phe Leu Ala Leu Ala Val Leu Val Thr Thr Val Leu Trp Ala Val Ile
35 40 45
Leu Ser Ile Leu Leu Ser Lys Ala Ser Thr Glu Arg Ala Ala Leu Leu
50 55 60
Asp Gly His Asp Leu Leu Arg Thr Asn Ala Ser Lys Gln Thr Ala Ala
65 70 75 80
Leu Gly Ala Leu Lys Glu Glu Val Gly Asp Cys His Ser Cys Cys Ser
85 90 95
Gly Thr Gln Ala Gln Leu Gln Thr Thr Arg Ala Glu Leu Gly Glu Ala
100 105 110
Gln Ala Lys Leu Met Glu Gln Glu Ser Ala Leu Arg Glu Leu Arg Glu
115 120 125
Arg Val Thr Gln Gly Leu Ala Glu Ala Gly Arg Gly Arg Glu Asp Val
130 135 140
Arg Thr Glu Leu Phe Arg Ala Leu Glu Ala Val Arg Leu Gln Asn Asn
145 150 155 160
Ser Cys Glu Pro Cys Pro Thr Ser Trp Leu Ser Phe Glu Gly Ser Cys
165 170 175
Tyr Phe Phe Ser Val Pro Lys Thr Thr Trp Ala Ala Ala Gln Asp His
180 185 190
Cys Ala Asp Ala Ser Ala His Leu Val Ile Val Gly Gly Leu Asp Glu
195 200 205
Gln Gly Phe Leu Thr Arg Asn Thr Arg Gly Arg Gly Tyr Trp Leu Gly
210 215 220
Leu Arg Ala Val Arg His Leu Gly Lys Val Gln Gly Tyr Gln Trp Val
225 230 235 240
Asp Gly Val Ser Leu Ser Phe Ser His Trp Asn Gln Gly Glu Pro Asn
245 250 255
Asp Ala Trp Gly Arg Glu Asn Cys Val Met Met Leu His Thr Gly Leu
260 265 270
Trp Asn Asp Ala Pro Cys Asp Ser Glu Lys Asp Gly Trp Ile Cys Glu
275 280 285
Lys Arg His Asn Cys
290
<210>2
<211>334
<212>PRT
<213>Artificial sequence
<220>
<223>
<400>2
Met Lys Met Ala Ser Ser Leu Ala Phe Leu Leu Leu Asn Phe His Val
1 5 10 15
Ser Leu Leu Leu Val Gln Leu Leu Thr Pro Cys Ser Ala Gln Phe Ser
20 25 30
Val Leu Gly Pro Ser Gly Pro Ile Leu Ala Met Val Gly Glu Asp Ala
35 40 45
Asp Leu Pro Cys His Leu Phe Pro Thr Met Ser Ala Glu Thr Met Glu
50 55 60
Leu Lys Trp Val Ser Ser Ser Leu Arg Gln Val Val Asn Val Tyr Ala
65 70 75 80
Asp Gly Lys Glu Val Glu Asp Arg Gln Ser Ala Pro Tyr Arg Gly Arg
85 90 95
Thr Ser Ile Leu Arg Asp Gly Ile Thr Ala Gly Lys Ala Ala Leu Arg
100 105 110
Ile His Asn Val Thr Ala Ser Asp Ser Gly Lys Tyr Leu Cys Tyr Phe
115 120 125
Gln Asp Gly Asp Phe Tyr Glu Lys Ala Leu Val Glu Leu Lys Val Ala
130 135 140
Ala Leu Gly Ser Asn Leu His Val Glu Val Lys Gly Tyr Glu Asp Gly
145 150 155 160
Gly Ile His Leu Glu Cys Arg Ser Thr Gly Trp Tyr Pro Gln Pro Gln
165 170 175
Ile Gln Trp Ser Asn Ala Lys Gly Glu Asn Ile Pro Ala Val Glu Ala
180 185 190
Pro Val Val Ala Asp Gly Val Gly Leu Tyr Glu Val Ala Ala Ser Val
195 200 205
Ile Met Arg Gly Gly Ser Gly Glu Gly Val Ser Cys Ile Ile Arg Asn
210 215 220
Ser Leu Leu Gly Leu Glu Lys Thr Ala Ser Ile Ser Ile Ala Asp Pro
225 230 235 240
Phe Phe Arg Ser Ala Gln Pro Trp Ile Ala Ala Leu Ala Gly Thr Leu
245 250 255
Pro Ile Leu Leu Leu Leu Leu Ala Gly Ala Ser Tyr Phe Leu Trp Arg
260 265 270
Gln Gln Lys Glu Ile Thr Ala Leu Ser Ser Glu Ile Glu Ser Glu Gln
275 280 285
Glu Met Lys Glu Met Gly Tyr Ala Ala Thr Glu Arg Glu Ile Ser Leu
290 295 300
Arg Glu Ser Leu Gln Glu Glu Leu Lys Arg Lys Lys Ile Gln Tyr Leu
305 310 315 320
Thr Arg Gly Glu Glu Ser Ser Ser Asp Thr Asn Lys Ser Ala
325 330
<210>3
<211>584
<212>PRT
<213>Artificial sequence
<220>
<223>
<400>3
Met Lys Met Ala Ser Ser Leu Ala Phe Leu Leu Leu Asn Phe His Val
1 5 10 15
Ser Leu Phe Leu Val Gln Leu Leu Thr Pro Cys Ser Ala Gln Phe Ser
20 25 30
Val Leu Gly Pro Ser Gly Pro Ile Leu Ala Met Val Gly Glu Asp Ala
35 40 45
Asp Leu Pro Cys His Leu Phe Pro Thr Met Ser Ala Glu Thr Met Glu
50 55 60
Leu Arg Trp Val Ser Ser Ser Leu Arg Gln Val Val Asn Val Tyr Ala
65 70 75 80
Asp Gly Lys Glu Val Glu Asp Arg Gln Ser Ala Pro Tyr Arg Gly Arg
85 90 95
Thr Ser Ile Leu Arg Asp Gly Ile Thr Ala Gly Lys Ala Ala Leu Arg
100 105 110
Ile His Asn Val Thr Ala Ser Asp Ser Gly Lys Tyr Leu Cys Tyr Phe
115 120 125
Gln Asp Gly Asp Phe Tyr Glu Lys Ala Leu Val Glu Leu Lys Val Ala
130 135 140
Ala Leu Gly Ser Asp Leu His Ile Glu Val Lys Gly Tyr Glu Asp Gly
145 150 155 160
Gly Ile His Leu Glu Cys Arg Ser Thr Gly Trp Tyr Pro Gln Pro Gln
165 170 175
Ile Lys Trp Ser Asp Thr Lys Gly Glu Asn Ile Pro Ala Val Glu Ala
180 185 190
Pro Val Val Ala Asp Gly Val Gly Leu Tyr Ala Val Ala Ala Ser Val
195 200 205
Ile Met Arg Gly Ser Ser Gly Gly Gly Val Ser Cys Ile Ile Arg Asn
210 215 220
Ser Leu Leu Gly Leu Glu Lys Thr Ala Ser Ile Ser Ile Ala Asp Pro
225 230 235 240
Phe Phe Arg Ser Ala Gln Pro Trp Ile Ala Ala Leu Ala Gly Thr Leu
245 250 255
Pro Ile Ser Leu Leu Leu Leu Ala Gly Ala Ser Tyr Phe Leu Trp Arg
260 265 270
Gln Gln Lys Glu Lys Ile Ala Leu Ser Arg Glu Thr Glu Arg Glu Arg
275 280 285
Glu Met Lys Glu Met Gly Tyr Ala Ala Thr Glu Gln Glu Ile Ser Leu
290 295 300
Arg Glu Lys Leu Gln Glu Glu Leu Lys Trp Arg Lys Ile Gln Tyr Met
305 310 315 320
Ala Arg Gly Glu Lys Ser Leu Ala Tyr His Glu Trp Lys Met Ala Leu
325 330 335
Phe Lys Pro Ala Asp Val Ile Leu Asp Pro Asp Thr Ala Asn Ala Ile
340 345 350
Leu Leu Val Ser Glu Asp Gln Arg Ser Val Gln Arg Ala Glu Glu Pro
355 360 365
Arg Asp Leu Pro Asp Asn Pro Glu Arg Phe Glu Trp Arg Tyr Cys Val
370 375 380
Leu Gly Cys Glu Asn Phe Thr Ser Gly Arg His Tyr Trp Glu Val Glu
385 390 395 400
Val Gly Asp Arg Lys Glu Trp His Ile Gly Val Cys Ser Lys Asn Val
405 410 415
Glu Arg Lys Lys Gly Trp Val Lys Met Thr Pro Glu Asn Gly Tyr Trp
420 425 430
Thr Met Gly Leu Thr Asp Gly Asn Lys Tyr Arg Ala Leu Thr Glu Pro
435 440 445
Arg Thr Asn Leu Lys Leu Pro Glu Pro Pro Arg Lys Val Gly Ile Phe
450 455 460
Leu Asp Tyr Glu Thr Gly Glu Ile Ser Phe Tyr Asn Ala Thr Asp Gly
465 470 475 480
Ser His Ile Tyr Thr Phe Pro His Ala Ser Phe Ser Glu Pro Leu Tyr
485 490 495
Pro Val Phe Arg Ile Leu Thr Leu Glu Pro Thr Ala Leu Thr Ile Cys
500 505 510
Pro Ile Pro Lys Glu Val Glu Ser Ser Pro Asp Pro Asp Leu Val Pro
515 520 525
Asp His Ser Leu Glu Thr Pro Leu Thr Pro Gly Leu Ala Asn Glu Ser
530 535 540
Gly Glu Pro Gln Ala Glu Val Thr Ser Leu Leu Leu Pro Ala His Pro
545 550 555 560
Gly Ala Glu Val Ser Pro Ser Ala Thr Thr Asn Gln Asn His Lys Leu
565 570 575
Gln Ala Arg Thr Glu Ala Leu Tyr
580
<210>4
<211>21bp
<212>DNA
<213>Artificial sequence
<220>
<223>
<400>4
gccacagatg gatctcatat c 21
<210>5
<211>21bp
<212>DNA
<213>Artificial sequence
<220>
<223>
<400>5
cccttctgca acaaccaatc a 21
<210>6
<211>1542bp
<212>DNA
<213>Artificial sequence
<220>
<223>
<400>6
atgaaaatgg caagtttcct ggccttcctt ctgctcaact ttcgtgtctg cctccttttg 60
cttcagctgc tcatgcctca ctcagctcag ttttctgtgc ttggaccctc tgggcccatc 120
ctggccatgg tgggtgaaga cgctgatctg ccctgtcacc tgttcccgac catgagtgca 180
gagaccatgg agctgaagtg ggtgagttcc agcctaaggc aggtggtgaa cgtgtatgca 240
gatggaaagg aagtggaaga caggcagagt gcaccgtatc gagggagaac ttcgattctg 300
cgggatggca tcactgcagg gaaggctgct ctccgaatac acaacgtcac agcctctgac 360
agtggaaagt acttgtgtta tttccaagat ggtgacttct atgaaaaagc cctggtggag 420
ctgaaggttg cagcactggg ttctgatctt cacgttgatg tgaagggtta caaggatgga 480
gggatccatc tggagtgcag gtccactggc tggtaccccc aaccccaaat acagtggagc 540
aacaacaagg gagagaacat cccgactgtg gaagcacctg tggttgcaga cggagtgggc 600
ctgtatgcag tagcagcatc tgtgatcatg agaggcagct ctggggaggg tgtatcctgt 660
accatcagaa gttccctcct cggcctggaa aagacagcca gcatttccat cgcagacccc 720
ttcttcagga gcgcccagag gtggatcgcc gccctggcag ggaccctgcc tgtcttgctg 780
ctgcttcttg ggggagccgg ttacttcctg tggcaacagc aggaggaaaa aaagactcag 840
ttcagaaaga aaaagagaga gcaagagttg agagaaatgg catggagcac aatgaagcaa 900
gaacaaagca caagagtgaa gctcctggag gaactcagat ggagaagtat ccagtatgca 960
tctcggggag agagacattc agcctataat gaatggaaaa aggccctctt caagcctgcg 1020
gatgtgattc tggatccaaa aacagcaaac cccatcctcc ttgtttctga ggaccagagg 1080
agtgtgcagc gtgccaagga gccccaggat ctgccagaca accctgagag atttaattgg 1140
cattattgtg ttctcggctg tgagagcttc atatcaggga gacattactg ggaggtggag 1200
gtaggggaca ggaaagagtg gcatataggg gtgtgcagta agaatgtgca gagaaaaggc 1260
tgggtcaaaa tgacacctga gaatggattc tggactatgg ggctgactga tgggaataag 1320
tatcggactc taactgagcc cagaaccaac ctgaaacttc ctaagccccc taagaaagtg 1380
ggggtcttcc tggactatga gactggagat atctcattct acaatgctgt ggatggatcg 1440
catattcata ctttcctgga cgtctccttc tctgaggctc tatatcctgt tttcagaatt 1500
ttgaccttgg agcccacggc cctgactatt tgtccagcgt ga 1542
<210>7
<211>1005bp
<212>DNA
<213>Artificial sequence
<220>
<223>
<400>7
atgaaaatgg caagttccct ggctttcctt ctgctcaact ttcatgtctc cctcctcttg 60
gtccagctgc tcactccttg ctcagctcag ttttctgtgc ttggaccctc tgggcccatc 120
ctggccatgg tgggtgaaga cgctgatctg ccctgtcacc tgttcccgac catgagtgca 180
gagaccatgg agctgaagtg ggtaagttcc agcctaaggc aggtggtgaa cgtgtatgca 240
gatggaaagg aagtggaaga caggcagagt gcaccgtatc gagggagaac ttcgattctg 300
cgggatggca tcactgcagg gaaggctgct ctccgaatac acaacgtcac agcctctgac 360
agtggaaagt acttgtgtta tttccaagat ggtgacttct atgaaaaagc cctggtggag 420
ctgaaggttg cagcactggg ttctaatctt cacgtcgaag tgaagggtta tgaggatgga 480
gggatccatc tggagtgcag gtccaccggc tggtaccccc aaccccaaat acagtggagc 540
aacgccaagg gagagaacat cccagctgtg gaagcacctg tggttgcaga tggagtgggc 600
ctatatgaag tagcagcatc tgtgatcatg agaggcggct ccggggaggg tgtatcctgc 660
atcatcagaa attccctcct cggcctggaa aagacagcca gcatttccat cgcagacccc 720
ttcttcagga gcgcccagcc ctggatcgca gccctggcag ggaccctgcc tatcttgctg 780
ctgcttctcg ccggagccag ttacttcttg tggagacaac agaaggaaat aactgctctg 840
tccagtgaga tagaaagtga gcaagagatg aaagaaatgg gatatgctgc aacagagcgg 900
gaaataagcc taagagagag cctccaggag gaactcaaga ggaaaaaaat ccagtacttg 960
actcgtggag aggagtcttc gtccgatacc aataagtcag cctga 1005
<210>8
<211>1755bp
<212>DNA
<213>Artificial sequence
<220>
<223>
<400>8
atgaaaatgg caagttccct ggctttcctt ctgctcaact ttcatgtctc cctcttcttg 60
gtccagctgc tcactccttg ctcagctcag ttttctgtgc ttggaccctc tgggcccatc 120
ctggccatgg tgggtgaaga cgctgatctg ccctgtcacc tgttcccgac catgagtgca 180
gagaccatgg agctgaggtg ggtgagttcc agcctaaggc aggtggtgaa cgtgtatgca 240
gatggaaagg aagtggaaga caggcagagt gcaccgtatc gagggagaac ttcgattctg 300
cgggatggca tcactgcagg gaaggctgct ctccgaatac acaacgtcac agcctctgac 360
agtggaaagt acttgtgtta tttccaagat ggtgacttct acgaaaaagc cctggtggag 420
ctgaaggttg cagcattggg ttctgatctt cacattgaag tgaagggtta tgaggatgga 480
gggatccatc tggagtgcag gtccactggc tggtaccccc aaccccaaat aaagtggagc 540
gacaccaagg gagagaacat cccggctgtg gaagcacctg tggttgcaga tggagtgggc 600
ctgtatgcag tagcagcatc tgtgatcatg agaggcagct ctggtggggg tgtatcctgc 660
atcatcagaa attccctcct cggcctggaa aagacagcca gcatatccat cgcagacccc 720
ttcttcagga gcgcccagcc ctggatcgcg gccctggcag ggaccctgcc tatctcgttg 780
ctgcttctcg caggagccag ttacttcttg tggagacaac agaaggaaaa aattgctctg 840
tccagggaga cagaaagaga gcgagagatg aaagaaatgg gatacgctgc aacagagcaa 900
gaaataagcc taagagagaa gctccaggag gaactcaagt ggaggaaaat ccagtacatg 960
gctcgtggag agaagtcttt ggcctatcat gaatggaaaa tggccctctt caaacctgcg 1020
gatgtgattc tggatccaga cacggcaaac gccatcctcc ttgtttctga ggaccagagg 1080
agtgtgcagc gtgctgaaga gccgcgggat ctgccagaca accctgagag atttgaatgg 1140
cgttactgtg tccttggctg tgaaaacttc acatcaggga gacattactg ggaggtggaa 1200
gtgggggaca gaaaagagtg gcatattggg gtatgtagta agaacgtgga gaggaaaaaa 1260
ggttgggtca aaatgacacc ggagaacgga tactggacta tgggcctgac tgatgggaat 1320
aagtatcggg ctctcactga gcccagaacc aacctgaaac ttcctgagcc tcctaggaaa 1380
gtggggatct tcctggacta tgagactgga gagatctcgt tctataatgc cacagatgga 1440
tctcatatct acacctttcc gcacgcctct ttctctgagc ctctatatcc tgttttcaga 1500
attttgacct tggagcccac tgccctgacc atttgcccaa taccaaaaga agtagagagt 1560
tcccccgatc ctgacctagt gcctgatcat tccctggaga caccactgac cccgggctta 1620
gctaatgaaa gtggggagcc tcaggctgaa gtaacatctc tgcttctccc tgcccaccct 1680
ggagctgagg tctccccttc tgcaacaacc aatcagaacc ataagctaca ggcacgcact 1740
gaagcacttt actga 1755
Claims (10)
1. suppress BTN3A expression and/or active material in the product with least one of following (1)-(5) is prepared
Application:
(1) treatment and/or pre- preventing tumor;
(2) growth of tumour cell is suppressed;
(3) maintenance or promotion of tumour cell dryness are suppressed;
(4) expression of tumour cell dryness correlated characteristic molecule is suppressed;
(5) inside tumor cells STAT3 phosphorylations are suppressed;
The BTN3A is following a1) or a2):
a1)BTN3A3;
A2) BTN3A2 and BTN3A3.
2. application according to claim 1, it is characterised in that:
The material of the suppression BTN3A expression and/or activity is following any:Disturb the RNA of BTN3A2 and BTN3A3 expression
Molecule, anti-LSECtin antibody, LSECtin micromolecular inhibitors, LSECtin soluble proteins, the RNA of interference LSECtin expression
Molecule, anti-BTN3A2 antibody, BTN3A2 micromolecular inhibitors, BTN3A2 soluble proteins, the RNA of interference BTN3A2 expression divide
Sub, anti-BTN3A3 antibody, BTN3A3 micromolecular inhibitors, BTN3A3 soluble proteins and the RNA molecule of interference BTN3A3 expression.
3. application according to claim 1 or 2, it is characterised in that:
The RNA molecule of interference BTN3A2 and the BTN3A3 expression and the RNA molecule of interference BTN3A3 expression are as follows
b1)-b4):
B1) the shRNA molecule shown in sequence 4;
B2) sequence 4 is deleted or increases or change one or several nucleotide, and with the nucleotide of 4 identical function of sequence;
B3) the shRNA molecule shown in sequence 5;
B4) sequence 5 is deleted or increases or change one or several nucleotide, and with the nucleotide of 5 identical function of sequence;
And/or the tumour cell dryness correlated characteristic molecule is Oct4 genes and/or Nanog genes and/or Sox genes;
And/or the growth for suppressing tumour cell is embodied in the tumor formation rate for reducing tumour cell and/or reduces tumour cell
Volume.
4. according to any application in claim 1-3, it is characterised in that:
The product is medicine;
And/or
The tumour is following c1) or c2):
C1) the tumour of BTN3A3 expression;
C2 the tumour of under) LSECtin is stimulated and BTN3A3 expression;
The tumour is specially breast cancer, liver cancer, stomach cancer, colon cancer, lung cancer, giant cell tumor of bone, kidney, carcinoma of parotid gland.
5. a kind of product, for its active ingredient to suppress the material of BTN3A expression and/or activity, the purposes of the product is as follows
(1) at least one of-(5):
(1) treatment and/or pre- preventing tumor;
(2) growth of tumour cell is suppressed;
(3) maintenance or promotion of tumour cell dryness are suppressed;
(4) expression of tumour cell dryness correlated characteristic molecule is suppressed;
(5) inside tumor cells STAT3 phosphorylations are suppressed;
The BTN3A is following a1) or a2):
a1)BTN3A3;
A2) BTN3A2 and BTN3A3.
6. product according to claim 5, it is characterised in that:The material of the suppression BTN3A expression and/or activity is such as
Under it is any:Disturb BTN3A2 and BTN3A3 expression RNA molecule, anti-LSECtin antibody, LSECtin micromolecular inhibitors,
LSECtin soluble proteins, interference LSECtin expression RNA molecule, anti-BTN3A2 antibody, BTN3A2 micromolecular inhibitors,
BTN3A2 soluble proteins, interference BTN3A2 expression RNA molecule, anti-BTN3A3 antibody, BTN3A3 micromolecular inhibitors,
BTN3A3 soluble proteins and the RNA molecule of interference BTN3A3 expression.
7. the product according to claim 5 or 6, it is characterised in that:
The RNA molecule of interference BTN3A2 and the BTN3A3 expression and the RNA molecule of interference BTN3A3 expression are as follows
b1)-b4):
B1) the shRNA molecule shown in sequence 4;
B2) sequence 4 is deleted or increases or change one or several nucleotide, and with the nucleotide of 4 identical function of sequence;
B3) the shRNA molecule shown in sequence 5;
B4) sequence 5 is deleted or increases or change one or several nucleotide, and with the nucleotide of 5 identical function of sequence;
And/or the tumour cell dryness correlated characteristic molecule is Oct4 genes and/or Nanog genes and/or Sox genes;
And/or the growth for suppressing tumour cell is embodied in the tumor formation rate for reducing tumour cell and/or reduces tumour cell
Volume.
8. according to any product in claim 5-7, it is characterised in that:
The product is medicine;
And/or
The tumour is following c1) or c2):
C1) the tumour of BTN3A3 expression;
C2 the tumour of under) LSECtin is stimulated and BTN3A3 expression;
The tumour is specially breast cancer, liver cancer, stomach cancer, colon cancer, lung cancer, giant cell tumor of bone, kidney, carcinoma of parotid gland.
Applications of the 9.BTN3A2 and/or BTN3A3 as target spot in immunotherapy of tumors;
And/or applications of the BTN3A2 and/or BTN3A3 as target spot in developing or designing immunotherapy of tumors medicine.
10. application according to claim 9, it is characterised in that:
The product is medicine;
And/or
The tumour is following c1) or c2):
C1) the tumour of BTN3A3 expression;
C2 the tumour of under) LSECtin is stimulated and BTN3A3 expression;
The tumour is specially breast cancer, liver cancer, stomach cancer, colon cancer, lung cancer, giant cell tumor of bone, kidney, carcinoma of parotid gland.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610952945.2A CN107998396B (en) | 2016-11-02 | 2016-11-02 | Target for tumor treatment and application thereof |
US16/346,316 US11634493B2 (en) | 2016-11-02 | 2017-11-02 | Tumor immunotherapy target and application thereof |
PCT/CN2017/109031 WO2018082590A1 (en) | 2016-11-02 | 2017-11-02 | Tumor immunotherapy target and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610952945.2A CN107998396B (en) | 2016-11-02 | 2016-11-02 | Target for tumor treatment and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107998396A true CN107998396A (en) | 2018-05-08 |
CN107998396B CN107998396B (en) | 2020-12-11 |
Family
ID=62048320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610952945.2A Active CN107998396B (en) | 2016-11-02 | 2016-11-02 | Target for tumor treatment and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107998396B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113398270A (en) * | 2021-07-20 | 2021-09-17 | 中国科学院上海营养与健康研究所 | Method for treating giant cell tumor of bone |
CN113679735A (en) * | 2021-08-23 | 2021-11-23 | 复旦大学附属中山医院 | Application of SLC7A11 gene in hepatocellular carcinoma interventional embolization operation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104906575A (en) * | 2014-03-12 | 2015-09-16 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Application of LSECtin as melanoma immunotherapy target |
CN105457024A (en) * | 2014-10-13 | 2016-04-06 | 李小彦 | Anti-butyrophilin-3 humanized antibody and application thereof |
-
2016
- 2016-11-02 CN CN201610952945.2A patent/CN107998396B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104906575A (en) * | 2014-03-12 | 2015-09-16 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Application of LSECtin as melanoma immunotherapy target |
CN105457024A (en) * | 2014-10-13 | 2016-04-06 | 李小彦 | Anti-butyrophilin-3 humanized antibody and application thereof |
Non-Patent Citations (2)
Title |
---|
SANDSTROM A.等: "The Intracellular B30.2 Domain of Butyrophilin 3A1 Binds Phosphoantigens to Mediate Activation of Human Vγ9Vδ2 T Cells.", 《IMMUNITY》 * |
YAMASHIRO H等: "Stimulation of human butyrophilin 3 molecules results in negative regulation of cellular immunity", 《JOURNAL OF LEUKOCYTE BIOLOGY》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113398270A (en) * | 2021-07-20 | 2021-09-17 | 中国科学院上海营养与健康研究所 | Method for treating giant cell tumor of bone |
CN113679735A (en) * | 2021-08-23 | 2021-11-23 | 复旦大学附属中山医院 | Application of SLC7A11 gene in hepatocellular carcinoma interventional embolization operation |
Also Published As
Publication number | Publication date |
---|---|
CN107998396B (en) | 2020-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Iwamoto et al. | The machinery for endocytosis of epidermal growth factor receptor coordinates the transport of incoming hepatitis B virus to the endosomal network | |
EP2558502B1 (en) | Tumor cell-derived microvesicles | |
CN105779386B (en) | A kind of application of mescenchymal stem cell in preparation treatment M5 type leukemia medicament | |
CN105979780A (en) | Glucocorticoid inhibitors for treatment of prostate cancer | |
CN106191067A (en) | Circular rna circ NFATC3 and application thereof | |
CN106086078B (en) | A kind of CAR T cell toxicities indicate carrier | |
CN111041064A (en) | Method for evaluating CAR-T killing activity in vitro | |
JP2023541542A (en) | Methods and compositions for treating coronavirus | |
CN109453382A (en) | EphrinA1 albumen is preparing the application in the drug for inhibiting tumor cell invasion, transfer | |
CN107998396A (en) | A kind of target spot of oncotherapy and its application | |
CN111607571A (en) | Replicative oncolytic adenovirus for specifically activating immune co-stimulation pathway and preparation method and application thereof | |
CN108014327A (en) | For the immunotherapy of tumors target of tumor-associated macrophage | |
CN102772806B (en) | Application of micromolecular nucleic acid miR-302 for treating or preventing testicular cancer | |
Xu et al. | Lentinan up-regulates microRNA-340 to promote apoptosis and autophagy of human osteosarcoma cells | |
CN107281172A (en) | Application of the melbine in the medicine for preparing cervical carcinoma | |
CN115747292A (en) | In-vitro efficacy detection method of ADC (azodicarbonamide) medicament | |
CN104083368A (en) | Application of G-1 in preparation of G protein coupled receptor 30-based triple negative breast cancer targeting drugs | |
Soca-Chafre et al. | Airborne particulate matter upregulates expression of early and late adhesion molecules and their receptors in a lung adenocarcinoma cell line | |
CN113476466A (en) | Application of baicalin in preparation of drug resistant to chronic myeloid leukemia | |
CN103131674A (en) | Chinese hamster ovary (CHO) cell line capable of expressing Rta albumen of Elzatein-Barn (EB) virus stably and efficiently, creation method and application thereof and cell base built by CHO cell line | |
CN106702002A (en) | Biomarker for lung adenocarcinoma diagnosis and treatment | |
Cheng et al. | Interleukin-1 alpha and high mobility group box-1 secretion in polyinosinic: polycytidylic-induced colorectal cancer cells occur via RIPK1-dependent mechanism and participate in tumourigenesis | |
Chen et al. | Construction of IMMS Containing Multi-site Liposomes for Dynamic Monitoring of Blood CTC in Patients with Osimertinib-resistant Non-small-cell Lung Cancer and its Mechanism | |
CN103417982A (en) | Application of human original longevity assurance gene 2 in preparation of drugs for improving sensitivity of breast cancer cells against anticancer drugs | |
CN109364252A (en) | IFN-I to ARG1 induction access is inhibited to prepare the application in antineoplastic pharmaceutical compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |